GSK agreed to acquire ex-China rights to Hutchmed’s HMPL-A830 in a deal worth up to $1.295 billion, with an initial $110 million upfront payment. The asset is an antibody-targeted therapy conjugate designed to deliver a KRAS inhibitor payload to EGFR-expressing tumors, combining EGFR targeting with KRAS pathway disruption, and GSK plans to run global Phase 1 development before taking over subsequent activity in licensed territories.